Trials / Not Yet Recruiting
Not Yet RecruitingNCT06408623
Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer
A Phase II Clinical Study on the First-line Treatment of Advanced Liver Cancer With Chidamide Combined With Sintilimab and Bevacizumab
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore the safety and tolerability of chidamide in combination with Sintilimab and bevacizumab in patients with advanced liver cancer, to determine the recommended dose for this combination regimen, and to explore preliminary efficacy data. And based on the tumor immune microenvironment multidimensional (lymphocyte subsets, multiple cytokines, multicolor fluorescence immunohistochemistry, single cell sequencing, etc.) to explore the therapeutic efficacy related markers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | chidamide combined with Sintilimab and bevacizumab | chidamide combined with Sintilimab and bevacizumab |
Timeline
- Start date
- 2024-05-15
- Primary completion
- 2025-05-15
- Completion
- 2026-05-15
- First posted
- 2024-05-10
- Last updated
- 2024-05-10
Source: ClinicalTrials.gov record NCT06408623. Inclusion in this directory is not an endorsement.